Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China. - Wikidata - awgldk - TriplyDB

Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China.

Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China.

http://www.wikidata.org/entity/Q30399259

about

Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009.Two years after pandemic influenza A/2009/H1N1: what have we learned?Guillain-Barré Syndrome, Influenza Vaccination, and Antecedent Respiratory and Gastrointestinal Infections: A Case-Centered Analysis in the Vaccine Safety Datalink, 2009-2011.Spontaneous reporting of adverse events following pandemic influenza A (H1N1) immunization in a reference center in the State of São Paulo, Brazil.Pandemic A/H1N1 2009 influenza vaccination, preceding infections and clinical findings in UK children with Guillain-Barré syndrome.The pandemic influenza A (H1N1) 2009 vaccine does not increase the mortality rate of idiopathic interstitial pneumonia: a matched case-control study.Pandemic H1N1 Vaccination and Incidence of Acute Disseminated Encephalomyelitis in Manitoba.Meta-analysis of the immunogenicity and tolerability of pandemic influenza A 2009 (H1N1) vaccines.No evidence of a link between influenza vaccines and Guillain-Barre syndrome-associated antiganglioside antibodies Assessing vaccine safety communication with healthcare providers in a large urban county.Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden.Effectiveness and safety of the A-H1N1 vaccine in children: a hospital-based case-control study.Publication delay of randomized trials on 2009 influenza A (H1N1) vaccination.[Guillain-Barré syndrome after exposure to influenza].Polymyositis following Pandemic Influenza A (H1N1) and 2009-10 Seasonal Trivalent Vaccines Surveillance for adverse events following immunization from 2008 to 2011 in Zhejiang Province, China.Infectious optic neuropathies: a clinical update Passive enhanced safety surveillance for Vaxigrip and Intanza 15 µg in the United Kingdom and Finland during the northern hemisphere influenza season 2015/16.Adult preferences for influenza vaccines with lower likelihood of side effects Acute disseminated encephalomyelitis with severe neurological outcomes following virosomal seasonal influenza vaccine Ontology-based combinatorial comparative analysis of adverse events associated with killed and live influenza vaccines.Safety and Immunogenicity of Cell Culture-Derived A/H3N2 Variant Influenza Vaccines: A Phase I Randomized, Observer-Blind, Dose-Ranging Study.Technical guidelines for the application of seasonal influenza vaccine in China (2014-2015).Safety of measles-containing vaccines in post-marketing surveillance in Anhui, China Guillain-Barré Syndrome in India: population-based validation of the Brighton criteria.Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccination.A global survey of adverse event following immunization surveillance systems for pregnant women and their infants Vaccine Safety Surveillance Systems: Critical Elements and Lessons Learned in the Development of the US Vaccine Safety Datalink's Rapid Cycle Analysis Capabilities.Guillain-Barre syndrome during the 2009-2010 H1N1 influenza vaccination campaign: population-based surveillance among 45 million Americans Vaccine allergies Active surveillance for adverse events following immunization.Incidence of adverse events among healthcare workers following H1N1 Mass immunization in Ghana: a prospective study.Viral RNA in the influenza vaccine may have contributed to the development of ANCA-associated vasculitis in a patient following immunisation.Randomized trial investigating the safety and efficacy of influenza vaccination in patients with antineutrophil cytoplasmic antibody-associated vasculitis.Vaccination, herd behavior, and herd immunity.A case of post-vaccination optic neuritis: coincidence or causative?The "urban myth" of the association between neurological disorders and vaccinations.The safety of H1N1 vaccine in children in Saudi Arabia: a cohort study using modern technology in a developing country.Pandemic influenza vaccination for healthcare workers in primary care: good progress, but higher uptake required.Observational safety study of specific outcomes after trivalent cell culture seasonal influenza vaccination (Optaflu® ) among adults in THIN database of electronic UK primary healthcare records.

P2860

Q30224646-5FE17F58-B46A-4813-BC8E-364CA8A3B80A Q30224656-4A9BAC00-96E6-4FDB-BD27-BE56225545DE Q30351998-B9F55EE5-F5A2-4F04-822F-B6058FC3984E Q30352113-2A4F84EB-0284-409C-A2A6-3C77BA3E1DD9 Q30359657-13386805-621C-4041-AAAE-C4441FA99127 Q30359671-61DFCC64-A079-4E2D-A287-3119A4D8AD41 Q30392687-6A622CC1-5628-4E3F-978A-B1499CB92387 Q30407050-A1B8B287-01EF-43B3-BD5A-4712C6369C38 Q30407561-5DD7D060-A4D7-4C0D-9C09-3B9CF230EC09 Q30407586-69AB2757-3CB5-4BBC-A3E7-C3C2A74EC31F Q30408080-B0CC7EA1-FAE5-4E08-90A0-68D73DEADBFF Q30408530-57428452-2C52-451B-95AF-E436061AA80D Q30410554-2A4550FB-F40E-46EF-8614-C3943C6DC11A Q30415924-3B9CA1C6-B1F6-4569-86E7-541FB07CDC72 Q30420816-D2D6C468-4F0A-4D16-9CA7-3CB8A05F43EA Q30424745-DBDE21C7-20D0-45B3-A0A2-BF1312CE6CC4 Q33585443-0B280599-ED19-41E5-B3C8-FFDEC74212D4 Q33698062-B3436698-8F43-4826-B6EC-565F17D0545A Q34290871-4EACA905-5071-48C1-A8EE-BE817C5A74DF Q34291128-20FA2EBB-8F75-4048-8D76-E3EE46892F09 Q34499848-CA8CA625-78AC-4444-9ABF-881B99E28157 Q35974403-04001EFC-9D23-4A02-B3DF-39783AF62E01 Q36256314-66F93ACB-F38E-4193-B698-CE53E58494E5 Q36278634-99C0C474-B109-4109-8EB6-B95306DCD553 Q36800813-6119F403-7569-416F-9876-FD1A3D69746F Q36882923-91151B32-1F31-4F5B-B2C3-E6F6A452C70A Q37197142-BBFFDA30-6B76-4F1D-843B-48D22933A63A Q37327861-7CD83AD7-687C-4D6C-8B62-DE47F3FAEC0F Q37463235-2BF708FA-5B25-4B13-B276-AFDDFAD39447 Q37473533-DAEDEAF4-1E8B-43B0-B13A-C9A9C78421C7 Q38172268-A0EC408E-6103-41DA-8BAC-5C7E9E396C89 Q40254133-A0F1E950-35DD-4FD7-A3F9-354A4C411746 Q41371533-70DA2DBD-98EC-4ED8-B5C3-FE3A04810BE5 Q42172279-671FE780-4E1B-4B0C-91A3-C25BC88064FB Q42262155-EBCA9D00-BC6E-4018-8754-CEF2791FCC68 Q42344143-F56B4E43-52BD-42C0-937A-DB6F062B4132 Q43080823-083C720E-7E1A-46AE-AD6A-140A3D8E2289 Q43171845-7A66CB77-B68E-4D4A-A1BC-C6469A2AAE14 Q46732615-D9C464C8-174B-4BB7-AE18-A8A249DE0FC1 Q48274084-0E38C9E7-1F43-4F2C-8B22-0429849F106B

P2860

Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China.

http://www.wikidata.org/entity/Q30399259

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China.

@ast

Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China.

@en

type

label

Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China.

@ast

Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China.

@en

prefLabel

Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China.

@ast

Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China.

@en

P1433

Q30399259-AB27DAFC-0387-4F59-BC47-E0B8C57791B9

P1476

Q30399259-CC272B2E-BA28-48DC-AB9F-19B46B76FD84

P2093

Q30399259-0163B7E3-D23E-45E7-AFE8-668302368F19

Q30399259-0EF5C4A3-F2A7-43C0-B30B-D8313105A563

Q30399259-118BAB52-DEB5-4497-8D19-9C13715E975D

Q30399259-21F7F57C-0688-4800-9B26-4C4FCF51156C

Q30399259-59157ED2-C6F5-4FCD-87A1-0A9E18EBD60A

Q30399259-5C5EC140-C607-412E-A73B-D9077609D1AC

Q30399259-64DA6CAB-A7D1-4F52-8AF0-8A080E2255C6

Q30399259-7029790D-44C2-4164-92BF-45D0D9B46048

Q30399259-80181E16-5C79-48D9-9792-B46AE5B43C43

Q30399259-8C7018C9-4E8A-4BEB-AF45-22806D34640A

P304

Q30399259-65DB7D5F-AEC6-4ABF-8620-BA66D88E5FD6

P31

Q30399259-4B30BAB2-3451-4393-BB08-6DE3D70D2F34

P356

Q30399259-93E86FE2-80A3-4EE8-BBB7-B280342EAA2D

P407

Q30399259-BD74AC88-5C73-4B32-AA9B-8228DFAAD096

P433

Q30399259-32F62519-6919-46D6-83A8-688184D055F8

P478

Q30399259-A1B90482-7BFA-4EA3-B0D7-46D62047EFA2

P577

Q30399259-9256D707-65F4-4680-AFC8-CF829D64F096

P698

Q30399259-C55BDEC8-CBD4-4719-B85A-BF21E8B2DBC0

P356

P1433

The New England Journal of Medicine

P1476

Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China.

@en

P2093

Bao-Ping Zhu

http://www.w3.org/2001/XMLSchema#string

Bing-Bing Wu

http://www.w3.org/2001/XMLSchema#string

Da-Peng Yin

http://www.w3.org/2001/XMLSchema#string

Da-Wei Liu

http://www.w3.org/2001/XMLSchema#string

Di-Sha Xu

http://www.w3.org/2001/XMLSchema#string

Hong-Hong Bao

http://www.w3.org/2001/XMLSchema#string

Hua-Qing Wang

http://www.w3.org/2001/XMLSchema#string

Hui-Ming Luo

http://www.w3.org/2001/XMLSchema#string

Jing-Shan Zheng

http://www.w3.org/2001/XMLSchema#string

Ke-Li Li

http://www.w3.org/2001/XMLSchema#string

P304

638-647

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1008553

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

364

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21288090

http://www.w3.org/2001/XMLSchema#string